CompanyGraph
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionProfit margin is 116.3%, higher than 95% of its Biotechnology peers (median -47.7%)
- FinancialsAltman Z-Score 3.36: safe zone
- Interpretations10 currently firing — 10
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
900.00MUSDvs all stocks (USD)
Trailing P/E
2.85xvs Biotechnology peers
Revenue (TTM)
276.78MUSDvs all stocks (USD)
Profit Margin
116.30%vs Biotechnology peers
Beta
1.20xvs all stocks
52-Week Change
67.58%vs all stocks
Market Capitalization
900.00MUSDvs all stocks (USD)
Enterprise Value
844.62MUSDvs all stocks (USD)
Trailing P/E
2.85xvs Biotechnology peers
Forward P/E
9.75xvs Biotechnology peers
PEG Ratio
-0.0396xvs Biotechnology peers
Price to Sales (TTM)
3.25xvs Biotechnology peers
Price to Book (MRQ)
2.11xvs Biotechnology peers
Enterprise to Revenue
3.05xvs Biotechnology peers
Enterprise to EBITDA
9.42xvs Biotechnology peers
Gross Margin
89.17%vs Biotechnology peers
Profit Margin
116.30%vs Biotechnology peers
Operating Margin
29.95%vs Biotechnology peers
Return on Assets (TTM)
14.95%vs Biotechnology peers
Return on Equity (TTM)
126.90%vs Biotechnology peers
Revenue (TTM)
276.78MUSDvs all stocks (USD)
Revenue per Share (TTM)
15.12USDUpdated Sep 28, 2026Quarterly Revenue Growth
-22.60%vs Biotechnology peers
Gross Profit (TTM)
209.27MUSDvs all stocks (USD)
EBITDA (TTM)
94.03MUSDvs all stocks (USD)
Net Income (TTM)
321.91MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-71.00%vs Biotechnology peers
Operating Cash Flow (TTM)
79.39MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-31.76MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
294.28MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
19.62MUSDFY2025 · Dec 31, 2025Gross Profit
274.66MUSDFY2025 · Dec 31, 2025Operating Income
125.47MUSDvs all stocks (USD)
Pre-tax Income
121.83MUSDFY2025 · Dec 31, 2025Income Tax Expense
-245.20MUSDFY2025 · Dec 31, 2025Net Income
367.02MUSDFY2025 · Dec 31, 2025EBIT
129.15MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
131.56MUSDFY2025 · Dec 31, 2025Research & Development
33.30MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
115.90MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
3.68MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
7.32MUSDFY2025 · Dec 31, 2025EPS (Basic)
20.40USDFY2025 · Dec 31, 2025EPS (Diluted)
19.48USDFY2025 · Dec 31, 2025Basic Shares Outstanding
17.99MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
17.99MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
367.02MUSDFY2025 · Dec 31, 2025Operating Cash Flow
87.20MUSDFY2025 · Dec 31, 2025Free Cash Flow
87.20MUSDDerived from operating cash flow minus capital expenditure. This filing charges 2.42M of depreciation against 0 of capital expenditure, and its own free-cash-flow line reads 75.66M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
40.64MUSDFY2025 · Dec 31, 2025Income Tax Paid
1.06MUSDFY2025 · Dec 31, 2025Interest Paid
6.57MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
367.02MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.42MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-245.85MUSDFY2025 · Dec 31, 2025Stock-based Compensation
12.71MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-39.98MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-10.15MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
3.85MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-2.82MUSDFY2025 · Dec 31, 2025Capital Expenditures
0.00USDFY2025 · Dec 31, 2025Net Intangibles (CF)
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-153.49MUSDFY2025 · Dec 31, 2025Sale of Investments
61.13MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-92.36MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
-7.50MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
-7.50MUSDFY2025 · Dec 31, 2025Shares Outstanding
18.65MSharesUpdated Sep 28, 2026Float Shares
14.84MSharesUpdated Sep 28, 2026Shares Short
3.19MSharesUpdated Sep 28, 2026Short Ratio
11.35daysvs all stocks
Short % of Shares Outstanding
17.54%vs all stocks
% Held by Insiders
3.35%vs all stocks
% Held by Institutions
89.22%vs all stocks
Total Cash (MRQ)
95.33MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
5.10USDUpdated Sep 28, 2026Total Debt (MRQ)
39.95MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0939xvs Biotechnology peers
Current Ratio (MRQ)
1.94xvs Biotechnology peers
Book Value per Share (MRQ)
22.81USDUpdated Sep 28, 2026Total Assets
513.59MUSDvs all stocks (USD)
Total Current Assets
240.17MUSDFY2025 · Dec 31, 2025Total Liabilities
122.11MUSDFY2025 · Dec 31, 2025Total Non-current Assets
273.43MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
22.88MUSDFY2025 · Dec 31, 2025Total Current Liabilities
99.24MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
40.58MUSDFY2025 · Dec 31, 2025Other Short-term Investments
114.38MUSDFY2025 · Dec 31, 2025Accounts Receivable
51.76MUSDFY2025 · Dec 31, 2025Inventory
11.51MUSDFY2025 · Dec 31, 2025Accounts Payable
7.19MUSDFY2025 · Dec 31, 2025Short-term Debt
30.43MUSDFY2025 · Dec 31, 2025Deferred Revenue
29.07MUSDFY2025 · Dec 31, 2025Other Current Liabilities
5.00MUSDFY2025 · Dec 31, 2025Long-term Debt
22.88MUSDFY2025 · Dec 31, 2025Common Stock (Book)
18.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.02BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
391.48MUSDvs all stocks (USD)
52-Week Low
24.95USDUpdated Sep 28, 202652-Week High
52.24USDUpdated Sep 28, 202652-Week Change
67.58%vs all stocks
Beta
1.20xvs all stocks
50-Day MA
43.42USDUpdated Sep 28, 2026200-Day MA
36.36USDUpdated Sep 28, 2026Avg 10-Day Volume
284.52KSharesUpdated Sep 28, 2026Avg 30-Day Volume
279.00KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
16.89USDUpdated Sep 28, 202610 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Three Asset-Base Ratios Elevated
It gets more sales from its assets than its industry does, and a lot of profit from them too.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Profit margin is 116.3%, higher than 95% of its Biotechnology peers (median -47.7%)Significant
Profit margin: 1.16Industry median: -0.48Industry P95: 0.42Peers compared: 260
Return on equity is 126.9%, higher than 95% of its Biotechnology peers (median -22.3%)Significant
Return on equity: 1.27Industry median: -0.22Industry P95: 0.23Peers compared: 260
P/E ratio is 2.85×, lower than 95% of its Biotechnology peers (median 32.17×)Notable
P/E ratio: 2.85Industry median: 32.17Industry P5: 6.16Peers compared: 260
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 321,908,992Operating Cash Flow (USD, TTM): 79,389,000
Financial Health
Altman Z-Score 3.36: safe zoneNotable
Altman Z-Score: 3.36
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
China Isotope & Radiation Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhuzhou Qianjin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hainan Haiyao Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Cloudbreak Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ceribell, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen YHLO Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Eis Eczacıbaşı İlaç ve Sanayi A.Ş.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Theravance Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jade Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Ardelyx Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Sk Biopharmaceuticals Co., Ltd.
10 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMinimal Tax and Interest DragFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsThree Asset-Base Ratios Elevated
Exelixis Inc.
9 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsThree Asset-Base Ratios Elevated
Games Workshop Group PLC
9 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsThree Asset-Base Ratios Elevated